ARTICLE | Company News
Aronex gets non-approvable letter for Atragen
January 8, 2001 8:00 AM UTC
ARNX received a second non-approvable letter from the FDA for its Atragen tretinoin injectable liposomal all-trans retinoic acid to treat patients with acute promyelocytic leukemia (APL) for whom ther...